Literature DB >> 31682384

Xiyanping injection therapy for children with mild hand foot and mouth disease: a randomized controlled trial.

Guoliang Zhang1, Yong Hou1, Yan Li1, Liyun He2, Liuping Tang3, Tong Yang4, Xinying Zou5, Qingxiong Zhu6, Shiyan Yan7, Baoju Huang8, Jindong Zhao9, Jihan Huang10.   

Abstract

OBJECTIVE: To evaluate the clinical effects of Xiyanping injection intervention in pediatric patients with mild hand foot and mouth disease (HFMD).
METHODS: A total of 329 patients were stratified and block-randomized for symptomatic treatment of HFMD and assigned to one of the following groups: Western Medicine (group A, n = 103), Xiyanping injection (group B, n = 109), or Xiyanping injection and symptomatic treatment using Western Medicine (group C, n = 117). During the trial, fever, rash, ulcers of the mouth were observed among participants in each group before and after treatment, and conversion rates from mild to severe HFMD were measured.
RESULTS: After 3-7 days' treatment, no significant differences in the conversion rates from mild to severe HFMD were observed among the three groups (P > 0.05). There was a significantly low number of patients with the onset time of antifebrile effect, vanished time of hand and foot rashes and cumulative time for the ulcers in the mouth vanished, among the three groups (P < 0.05, P < 0.01). The onset time of antifebrile effect of patients in groups B and C were markedly shorter compared with those in group A (P < 0.05, P < 0.01); there was no statically significant difference observed between groups B and C (P > 0.05). No significant differences were observed in the time for body temperature recovery among the three groups (P > 0.05). There were no significant differences in adverse effects among the three groups (P > 0.05).
CONCLUSION: Xiyanping injection together with use of Western Medicine is most effective for symptomatic treatment of mild HFMD. No severe adverse reactions were observed.

Entities:  

Keywords:  Antipyretic; Body temperature regulation; Hand foot and mouth disease; Randomized controlled trial; Xiyanping injection

Year:  2017        PMID: 31682384

Source DB:  PubMed          Journal:  J Tradit Chin Med        ISSN: 0255-2922            Impact factor:   0.848


  3 in total

1.  Discovery of Novel Andrographolide Derivatives as Antiviral Inhibitors against Human Enterovirus A71.

Authors:  Jie Kai Tan; Ran Chen; Regina Ching Hua Lee; Feng Li; Kun Dai; Guo-Chun Zhou; Justin Jang Hann Chu
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-18

Review 2.  Adverse Effects of Andrographolide Derivative Medications Compared to the Safe use of Herbal Preparations of Andrographis paniculata: Results of a Systematic Review and Meta-Analysis of Clinical Studies.

Authors:  Ya-Xi Shang; Chen Shen; Trine Stub; Si-Jia Zhu; Shu-Yu Qiao; Yu-Qi Li; Rui-Ting Wang; Jing Li; Jian-Ping Liu
Journal:  Front Pharmacol       Date:  2022-01-28       Impact factor: 5.810

3.  Deciphering the potential anti-COVID-19 active ingredients in Andrographis paniculata (Burm. F.) Nees by combination of network pharmacology, molecular docking, and molecular dynamics.

Authors:  Rongfang Xie; Zuan Lin; Chenhui Zhong; Shaoguang Li; Bing Chen; Youjia Wu; Liying Huang; Hong Yao; Peiying Shi; Jianyong Huang
Journal:  RSC Adv       Date:  2021-11-11       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.